Atlas Trials

Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC

Clinical trial NCT07050056 · RECRUITING

Trial details

NCT number
NCT07050056
Sponsor
Northern Jiangsu People's Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Resectable NSCLC
Start date
2025-08-01
Primary completion
2027-06-30
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.